Investigational drug · Phase 2
BMS-986435
Also called: MYK-224
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Heart Failure.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
9
Any phase or sponsor naming "BMS-986435"
First trial start
2023
Nov 7, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMS-986435", any sponsor or status.
Conditions studied
As listed on its trial records.
- Heart Failure
Approved drugs for the same conditions: Heart failure · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "BMS-986435" as an intervention, largest first.
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07226817 · 240 participants (planned) · Start Nov 12, 2025 · Primary completion Dec 17, 2026
Drug: BMS-986435 · For: Healthy Volunteers
Sites: Miami, Florida
- Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)Pivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06122779 · 227 participants · Start Nov 7, 2023 · Primary completion Dec 14, 2026
Drug: BMS-986435 · For: Heart Failure
Sites: Birmingham, Alabama; Lakewood, Colorado; Jacksonville, Florida · 86 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07248839 · 69 participants · Start Dec 15, 2025 · Primary completion Aug 20, 2026
Drug: BMS-986435 · For: Healthy Volunteers; Hepatic Impairment
Sites: Chandler, Arizona; Miami Lakes, Florida; San Antonio, Texas
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05304533 · 45 participants · Start Apr 21, 2022 · Primary completion Nov 14, 2022
Drug: MYK-224; Itraconazole and 1 more · For: Healthy Participants
Sites: Dallas, Texas
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05405543 · 36 participants · Start Jul 12, 2022 · Primary completion Nov 16, 2022
Drug: MYK-224 · For: Healthy Volunteers
Sites: Anaheim, California
- Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult ParticipantsCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06577259 · 25 participants · Start Sep 3, 2024 · Primary completion Feb 19, 2025
Drug: BMS-986435 · For: Healthy Participants
Sites: San Antonio, Texas
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06476821 · 20 participants · Start Jun 27, 2024 · Primary completion Oct 11, 2024
Drug: BMS-986435 · For: Healthy Volunteers
Sites: Xuhui District, China
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05556343 · 18 participants · Start Jan 18, 2023 · Primary completion Aug 19, 2024
Drug: MYK-224 · For: Cardiomyopathy, Hypertrophic
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 25 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05686096 · 7 participants · Start Jan 16, 2023 · Primary completion Apr 8, 2023
Drug: MYK-224 · For: Healthy Volunteers
Sites: Madison, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
- Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges.
Kukowka A, Droździk M · Biomolecules 2025
Also in development for Heart Failure
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- IRP101meta-fluorobenzylguanidine, 18F-MFBGPhase 34 trials
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Cardiovascular Diseases, Heart Failure, Ischemic Cardiomyopathy
- ZiltivekimabPhase 34 trials
Novo Nordisk · Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure
- HiCM-188 therapyPhase 32 trials
HELP Therapeutics Co., Ltd. · Heart Failure
- Qishen Yiqi Dripping Pills 2 bagsPhase 32 trials
Tasly Pharmaceutical Group Co., Ltd · Heart Failure, Chronic Heart Failure With Preserved Ejection Fraction
- IMR-687Tovinontrine, CRD-750Phase 23 trials
Cardurion Pharmaceuticals, Inc. · Heart Failure, Cardiovascular Diseases, Heart Diseases
- CDR132LPhase 22 trials
Novo Nordisk · Heart Failure
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.